Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dietrich Stephan
PharmaShots Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine
In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the disease-causing…
April 6, 2021
Viewpoints_Marie Schiller
PharmaShots Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App
In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc's insulin management technology into Lilly's connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc's BlueStar app which will be integrated…
April 5, 2021
Viewpoints_Mark Erlander
PharmaShots Interview: Cardiff Oncology’s Mark Erlander Shares Insight on the P-I Data of Onvansertib for Metastatic Colorectal Cancer
In an interview with PharmaShots, Mark Erlander, CEO of Cardiff Oncology shared his views on the data presented at the ASCO-GI Conference, P-Ib results of Onvansertib, what these results meant for the patients with this aggressive type of mCRC, and the company's other ongoing programs for Onvansertib, including metastatic castration-resistant prostate cancer and AML Shots: The data presented at ASCO-GI showed…
March 31, 2021
Viewpoints_Dr. Sezer, Peter C. Adamson and Israel Lowy
PharmaShots Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA’s Approval of Libtayo (cemiplimab) in Patients with NSCLC with High PD-L1 Expression
Shots: In an interview with PharmaShots, Dr. Ahmet Sezer,  Sanofi's Peter C. Adamson, and Regeneron's Israel Lowy shared their views on the US FDA's approval of Libtayo and the data supporting the approval. Regeneron and Sanofi received the US FDA's approval for Libtayo for the 1L treatment of patients with advanced NSCLC whose tumors have high PD-L1 expression (tumor proportion score =50%), as…
March 30, 2021
Viewpoints_Nirav Desai
PharmaShots Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2020
In an interview with PharmaShots, Nirav Desai, Global Clinical Development Lead at Takeda shared his views on TAK-721 data presented at ACG 2020 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 years…
March 29, 2021
Viewpoints_Dr. Todd D. Cohen
PharmaShots Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment
In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such treatments.…
March 25, 2021
Viewpoints_John Valliant
PharmaShots Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca
In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company's agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company's TATs platform & Fast-Clear linker technology and provide a glance at Fusion's portfolio. Shots:  Fusion to receive $5M up front and $40M as milestones & other payments. The…
March 24, 2021
In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2's smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment from the US government to scale the domestic manufacturing of their vaccine vials which are made from a new material that they spent the past 10+ years and $500M developing SiO2 have delivered the government enough vials to support 100M COVID-19 vaccine doses SiO2's Alabama facility went from manufacturing 10M vials per year to over 10M vials per month and their local workforce grew from 100 employees to over 500. Each vial manufactured by SiO2 is multi-dose and can hold anywhere from 8-10 doses of vaccine Tuba: Shed some light on SiO2 efforts in scaling up the manufacturing of vials to combat COVID-19. How do you feel being a part of Operation Warp Speed? Lawrence: It's been an honor to be part of this concept. The idea to help rebuild the critical medical infrastructure in the united states is great. The company is excited to help lead these efforts. We have added more than 500 new jobs, build new sophisticated manufacturing plants, and invented new technology. All of this is homegrown in the United States. Tuba: Discuss the funding received by the company from the US Government? How did this funding help in scaling up the manufacturing of their vaccine vials? Lawrence: We have received an investment from the US Government for $143 million. This is to help scale-out technology and manufacturing in support of the current and future pandemics. We have used this to build capacity to support more than 1 billion doses of vaccine. Tuba: How are SiO2's smart vials different from the traditional vials? Can we have a glance on the material used in the vials? Lawrence: https://www.youtube.com/watch?v=B_zBSS_XVCE Source: SiO2 Tuba: Can we have a glance on SiO2's patented barrier technology? Lawrence: The interior of the vial is covered with the barrier system coating, using plasma-enhanced chemical vapor deposition. A partially ionized gas mixture deposits a crystal-clear and ultra-thin barrier system that is covalently bonded to the polymer. The bond is so strong that the barrier system is rendered unremovable irrespective of chemical, thermal, or mechanical stress. The most interior protective layer is in direct contact with the vial's contents and is made of an organosilica material that is a mixture of silicon, oxygen, carbon, and hydrogen atoms. This patented composition was designed to resist dissolving in extremely high pH formulations, unlike ordinary glass. It also eliminates metal ions leaching into the drug formulation at extremely low pH formulations. The glass-like barrier layer is composed of pure silicon dioxide. This layer is extremely dense, which is an important characteristic of a barrier to oxygen, moisture, and other chemical compounds. And the final layer is composed of organosilica that creates a strong chemical bond to the plastic exterior and to the adjacent barrier layer. Tuba: What are the benefits of using SiO2's smart vials? Lawrence: SiO2 Materials Science's ready-to-use vial is the first of its kind, utilizing advanced materials optimized for biological drugs. Using our patented process, engineering, and materials science technologies, we've created a hybrid material that fuses all the benefits of glass with all the benefits of plastic, while eliminating the drawbacks of both. The material is a medical-grade polymer fused with a three-layer barrier system that protects contents from oxygen, moisture, leachables, and any compounds that can originate from the environment, the polymer, and label adhesives. Metal ions, leachables, and particles are seen commonly in conventional glass vials are virtually eliminated. The unique, patented vial provides an inert container for drugs and eliminates important problems facing biologic drug development. It eliminates contaminants associated with an immunogenic response such as subvisible particles and metal ions Ensures an oxygen and moisture barrier of glass with thermal stability down to -196 degrees centigrade Exhibits no leachable or extractable Exhibits no glass delamination .And is unbreakable even at cryogenic temperatures. All of these attributes make the SiO2 vials ideal for bioengineered vaccines, cell & gene therapies, and antibody-drug conjugates. Tuba: Apart from Moderna, who else are you working with that you can publicly mention? Lawrence: We can publicly only mention Moderna for Covid. We are working with a number of other covid vaccine and therapeutic manufacturers. They are testing our vials in their clinical trials. Beyond Covid, we have been working with Novartis and many other leading pharma companies. Tuba: Can you share other insights with our readers about the SiO2's growth? Lawrence: We have grown from 100 employees to over 500 employees. We have grown from 1 factory to 4 factories. All this was done in the last 6 months of 2020. Our growth continues as we support not only Covid but many other companies developing advanced biological drugs and therapies. Main Image Source: The Conversation About Author: Mr. Ganti looks after the day-to-day operations of SiO2 Materials Science. He brings more than 25 years of building commercial organizations, leading billion-dollar P&Ls, creating award-winning marketing campaigns, and driving growth initiatives in the Pharmaceutical, Consumer Products, and Data Analytics space. Related Post: ViewPoints Interview: Biogen's Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza
PharmaShots Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines
In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2's smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment from the US government to scale the domestic…
March 22, 2021
Load more